Harvard Bioscience (HBIO) Assets Average (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Assets Average data on file, last reported at $79.0 million in Q1 2026.

• On a quarterly basis, Assets Average fell 23.46% year-over-year to $79.0 million in Q1 2026; TTM through Mar 2026 was $79.0 million, a 23.46% decrease from a year earlier, with the FY2025 full-year figure at $103.4 million, down 21.7% from the prior year.
• Assets Average for Q1 2026 stood at $79.0 million, roughly flat from $79.0 million in the prior quarter.
• Over the last five years, Assets Average for HBIO reached as high as $160.2 million in Q1 2022 and fell as low as $79.0 million in Q1 2026.
• Historically, Assets Average has averaged $125.3 million across 5 years, with a median of $135.3 million in 2024.
• Across the five-year window, Assets Average climbed 4.19% in 2022 and tumbled 39.23% in 2025, its largest moves.
• Year by year, Assets Average stood at $146.2 million in 2022, then fell by 5.22% to $138.6 million in 2023, then slipped by 6.94% to $128.9 million in 2024, then plunged by 38.71% to $79.0 million in 2025, then decreased by 0.03% to $79.0 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $79.0 million in Q1 2026, $79.0 million in Q4 2025, and $79.0 million in Q3 2025.